Shares of ALEBUND-B (HKEX: 09637) surged more than 10% during intraday trading. At the time of writing, the stock is up 7.20%, trading at HK$31.28 with a turnover of HK$9.07 million.

On June 29, the company received simultaneous share purchases from two major institutional shareholders. Singapore's sovereign wealth fund, GIC Private Limited, acquired 872,000 shares at an average price of HK$44.0844 per share, involving approximately HK$38.44 million. This increased its total holding to 16.10 million shares, representing a 7.09% stake. On the same day, LAV Asset Management (Hong Kong) Limited purchased 450,000 shares at an average price of HK$45.0615 per share, involving about HK$20.28 million. This raised its total holding to approximately 16.35 million shares, or a 7.20% stake. Combined, the two institutions acquired over 1.32 million shares, investing a total of around HK$58.72 million, demonstrating strong confidence in the long-term value of ALEBUND-B.

Significant Strategic Move

It is noteworthy that GIC, managing over US$936 billion in global assets, is renowned for its stringent risk controls and ultra-long-term investment horizon. This move marks GIC's first participation as a cornerstone investor in the IPO of a Hong Kong-listed 18A company in recent years, breaking from its past practice of primarily investing in established pharmaceutical assets on the secondary market. In fact, GIC has been a long-term partner of ALEBUND-B, having initially invested during the company's B+ funding round and subsequently increasing its stake. For a sovereign wealth fund, this sustained, "running alongside" investment approach is a stronger indicator of deep confidence in the company's fundamentals and management execution than making a single, large concentrated bet.